AdipoPharma Advances PATAS into Phase 1b Clinical Trial in Patients with Type 2 Diabetes First participants with Type 2 diabetes dosed in multiple ascending dose (MAD) study evaluating AdipoPharma’s first-in-class insulin sensitizer Advancement follows successful completion of the single ascending dose (SAD) phase, where PATAS was well tolerated with no serious adverse events Oct. 27, 2026 -- AdipoPharma, a clinical-stage biotechnology company developing therapies that target adipocyte dysfunc

- Grants Astellas exclusive option to obtain worldwide license to develop and commercialize DAX-044, with Audax having the option to co-fund and co-promote DAX-044 in Australia and New Zealand - - Audax will fund and continue DAX-044 development into Phase 1 - - Total potential transaction value of up to US$1.34 billion,excluding royalties - Oct. 27, 2026 -- Astellas Pharma Inc. [TSE: 4503, President and CEO: Naoki Okamura, "Astellas"] and Audax Biosciences Pty Ltd ("Audax") today announced th

Phase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more migraine days per month.1 Atogepant (QULIPTA®) demonstrated superior efficacy across key clinical and functional outcomes, including reductions in monthly migraine days and improvements in headache-related disability, daily functioning and cognitive function.1 25% of Canadian households are impacted

Pathos AI uses the platform to identify patient sub-populations, redirect clinical trial strategies, and remove high-risk drug projects. Credit: Gorodenkoff / Shutterstock.com. Pathos AI has secured $237m in a Series E financing round to expand its clinical oncology pipeline and scale its AI drug development platform. The transaction values the US-based biotechnology company at approximately $3bn post-money. Bristol Myers Squibb (BMS) led the funding round, with further capital provided by exist

Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency EMCITATE is the first and only FDA-approved treatment for peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency in the United States Egetis RareLink™, the dedicated patient support program, provides access assistance, education and care coordination in partnership with PANTHERx® Rare Pharmacy Sept. 27, 2026 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockho

27 October 2026– Ferring Pharmaceuticals and Gameto today announced that they have signed an agreement for a global transaction under which Ferring would acquire Gameto. Completion remains subject to customary and other closing conditions. Until closing, the companies will continue to operate independently. The proposed transaction has a deal value of up to $1.3825 billion, subject to development, regulatory and commercial milestones. The transaction would bring together Gameto’s reproductive-h

October 26, 2026 Dragonfleye Therapeutics Corp. ("Dragonfleye" or the "Company"), a patient-centered, innovation-focused company developing minimally invasive treatments for pathologic conditions in ophthalmology using its platform technology, today announced that it completed two non-brokered private placements of common shares during 2026, raising aggregate gross proceeds of US$37.5 million (the "Offerings"). Participants included healthcare-dedicated investors and existing shareholders. Proc

Oct. 26, 2026 -- OncoHost, a technology company transforming the approach to predictive precision diagnostics for improved patient outcomes, today announced new research that was presented at the European Society for Medical Oncology (ESMO) 2026 Congress, taking place October 23–27 in Madrid, Spain. The study, "Plasma Proteomics Reveals the Biological Landscape of Tyrosine Kinase Inhibitors (TKI) Sensitivity in Metastatic Renal Cell Carcinoma," examines the biological basis of a model that uses

Oct. 27, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clinical trial evaluating zemprocitinib, an investigational, selective, second-generation oral Janus kinase 1 (JAK1) inhibitor, in adult patients with moderate-to-severe active rheumatoid arthritis (RA) who had experienced inadequate response or intolerance

TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability pro of systemic administration in an outpatient setting With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate (DCR) was 100%, with a median duration of response of 12.9 months and multiple participants continuing in active